You are here

  • Home
  • Archive
  • Volume 28, Issue 1
  • Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model

Article Text

Article menu

Download PDFPDF

Uterine Cancer
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
  1. Sebastien Taurin, PhD*,
  2. Chieh-Hsiang Yang, MS*,
  3. Maria Reyes, MD*,
  4. Sungpil Cho, PhD*,
  5. Demetrius M. Coombs, MD†,
  6. Elke A. Jarboe, MD*,‡,
  7. Theresa L. Werner, MD§,
  8. C. Matthew Peterson, MD∥ and
  9. Margit M. Janát-Amsbury, MD, PhD*
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Utah Health Sciences, Salt Lake City, UT;
  2. † Drexel University College of Medicine, Philadelphia, PA; and
  3. ‡ Division of Anatomical Pathology, Department of Pathology,
  4. § Division of Oncology, Department of Medicine, Huntsman Cancer Institute, and
  5. ∥ Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT.
  1. Address correspondence and reprint requests to Margit M. Janát-Amsbury, MD, PhD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Utah, 30 N 1900 E, SOM, 2A242 Salt Lake City, UT, 84132-0001. E-mail: margit.janat-amsbury{at}hsc.utah.edu.

Abstract

Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). This study evaluates the efficacy of AL3818 studying tumor regression in an orthotopic murine endometrial cancer model.

Methods We tested the cytotoxicity of AL3818 on a panel of 7 human endometrial cancer cell lines expressing either wild-type or mutant FGFR2 and also assessed the in vivo antitumor efficacy in a murine, orthotopic AN3CA endometrial cancer model. AL3818 was administered daily per os either alone or in combination with carboplatin and paclitaxel, which represent the current standard of adjuvant care for endometrial cancer.

Results AL3818 significantly reduces AN3CA cell number in vitro, characterized by high expression of a mutated FGFR2 protein. Daily oral administration of AL3818 (5 mg/kg) resulted in a complete response in 55% of animals treated and in a reduced tumor volume, as well as decreased tumor weights of AN3CA tumors by 94% and 96%, respectively, following a 29-day treatment cycle. Whereas carboplatin and paclitaxel failed to alter tumor growth, the combination with AL3818 did not seem to exhibit a superior effect when compared with AL3818 treatment alone.

Conclusions AL3818 shows superior efficacy for the treatment of endometrial cancer irresponsive to conventional carboplatin and paclitaxel combination and warrants further investigation.

  • Carboplatin and paclitaxel
  • Endometrial cancer
  • Mutant FGFR2
  • Orthotopic murine model
  • Tyrosine kinase inhibitor

https://doi.org/10.1097/IGC.0000000000001129

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.